Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
21 avr. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
13 avr. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
23 mars 2023 08h00 HE
|
Solid Biosciences Inc.
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - -...
Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery
21 mars 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at Barclays Global Healthcare Conference
07 mars 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Solid Biosciences to Present at SVB Securities Global Biopharma Conference
08 févr. 2023 08h00 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy
26 janv. 2023 08h00 HE
|
Solid Biosciences Inc.
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy...
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases
11 janv. 2023 08h00 HE
|
Solid Biosciences Inc.
Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac...
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
10 janv. 2023 08h00 HE
|
Solid Biosciences Inc.
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection...
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer
09 janv. 2023 16h26 HE
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today...